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Abstract: Antigen–antibody binding is regarded as one of the
most representative examples of specific molecular recognition
in nature. The simplistic view of antigenic recognition in terms
of a lock-and-key mechanism is obsolete, as it is evident that
both antigens and antibodies are flexible and can undergo
substantial mutual adaptation. This flexibility is the source of
complexities such as degeneracy and nonadditivity in antigenic
recognition. We have used surface plasmon resonance to study
the effects of combining multiple amino acid replacements
within the sequence of the antigenic GH loop of foot-and-
mouth disease virus. Our aim was 2-fold: to explore the extent
to which antigenic degeneracy can be extended in this
particular case, and to search for potential nonadditive effects
in introducing multiple amino acid replacements. Combined
analysis of one such multiply substituted peptide by SPR,
solution NMR and X-ray diffraction shows that antigenic
degeneracy can be expected as long as residues directly
interacting with the paratope are conserved and the peptide
bioactive folding is unaltered.
Abbreviations: 2D-1H NMR, two-dimensional proton nuclear
magnetic resonance; AAA, amino acid analysis; AM,
2-[4-aminomethyl-(2,4-dimethoxyphenyl)]phenoxyacetic
acid (linker); CA, analyte concentration; DdHa, conformational
chemical shift for proton a; DIEA, diisopropylethylamine;
DMF, N,N’-dimethylformamide; EDC,
N-ethyl-N’-dimethylaminopropylcarbodiimide; EDTA,
ethylenediaminotetraacetic acid; ESMS, electrospray ionization
mass spectrometry; Et3Si, triethylsilane; Fab, fragment antigen
binding; FMDV, foot-and-mouth disease virus; Fmoc,
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9-fluorenylmethyloxycarbonyl; HPLC, high-performance liquid
chromatography; IC50, 50% inhibition concentration; ka,
association rate constant (M–1s–1); KA, association thermodynamic
constant (M–1); kD, dissociation rate constant (s
–1); KD,
dissociation thermodynamic constant (M); Ki, solution affinity
constant (M–1); mAb, monoclonal antibody; MALDI-TOF MS,
matrix-assisted laser desorption–time-of-flight mass spectrometry;
MBHA, p-methylbenzhydrylamine resin; MeCN, acetonitrile;
MPLC, medium pressure liquid chromatography; NHS,
N-hydroxysuccinimide; NMM, N-methylmorpholine; NOE, nuclear
Overhauser effect; PBS, phosphate buffer saline; OD, optical
density; PBS, phosphate buffer saline; Req, equilibrium response;
Rimmob, immobilization response; Rmax, maximum response (RU);
RU, resonance units; r.p.m., revolutions per minute; SDS–PAGE,
sodium dodecyl sulfate–polyacrylamide gel electrophoresis; SPPS,
solid-phase peptide synthesis; SPR, surface plasmon resonance;
tBu, tert-butyl; TBTU, 2-(1H-benzotriazole-1-yl)-
1,1,3,3-tetramethyluronium tetrafluoroborate; TFA,
trifluoroacetic acid; TFE, 2,2,2-trifluoroethanol.
Antigen–antibody binding is regarded as one of the most
representative examples of specific molecular recognition in
nature (1). The exquisite specificity of immune reactions
is not only one of the pillars of host defense, but also the
basis for many helpful therapeutic and biotechnological
applications. The early, simplistic view of antibody–antigen
interactions taking place via lock-and-key mechanisms (2) is
inaccurate, as both antigens and antibodies are known to be
flexible and able to undergo considerable mutual adaptation
(3,4). Because epitope–paratope recognition operates at the
atomic rather than at the amino acid residue or sequence
level (5–7), a given epitope can be recognized by antibodies
devoid of sequential homology in their paratopes (8) and,
conversely, an antibody can recognize different epitopes
(e.g. peptides) that share little or no sequential similarity
(9). An additional example of complexity in antigen–
antibody recognition is the occasional observation of
nonadditivity, i.e. full recognition of multiple mutants
combining deleterious replacements or vice versa (10).
In our work with foot-and-mouth disease virus (FMDV)
(11,12), we have encountered examples of a relatively broad
recognition of variant peptides by antibodies (10,13–18).
These peptides were based on the main antigenic site of
FMDV, termed site A, located on the highly flexible GH loop
defined by residues 136–150 of the capsid protein VP1 in
FMDV isolate C-S8c1 (19). This loop is effectively mimicked
by peptide A15 (YTASARGDLAHLTTT), which has been
used in several studies on antigenic structure of this viral
site (13,20–22). Site A combines hypervariable segments
(137–140 148–150) with highly conserved residues such as
Leu144 and Leu147 and, especially, the integrin-binding motif
RGD, used as FMDV cell attachment site (20,21,23). This
duality makes site A an extremely interesting ground for
testing the boundaries of antigenic recognition. Systematic
studies carried out by Valero (24) have shown that amino
acid replacements at highly sensitive zones, such as
the RGD triplet, are mostly deleterious. In contrast, five
single point substitutions (Thr137 R Ile, Ala138 R Phe,
Ala140 R Pro, Gly142 R Ser and Thr148 R Ile) were found
to preserve antigenicity towards several anti-GH loop mAbs.
Although the first and last replacements are located at
each end of the loop, not in close contact with the antibody
(22), the other three are at positions known to be directly
involved in antibody recognition. Each of these three
replacements is also remarkable because of its non-
conservative character: Phe is much larger than Ala; Pro is
a known disrupter of secondary structure, which Ala is
not; finally, the Gly142 R Ser mutation affects the highly
conserved RGD motif. Studying the effect that every
possible combination of these five mutations has on
antigenicity provides a feasible way to explore the relative
limits of antigenic degeneracy at this particular site. In
addition, previous evidence of positive nonadditivity in
multiple substitutions within the GH loop (10,13,16–18)
encouraged us to look for possible synergistic effects in the
simultaneous combination of these amino acid replace-
ments. Therefore, we analyzed the 31 peptides (Table 1)
corresponding to the combination of the five mutations by
surface plasmon resonance (SPR) (25,26) against three
anti-GH loop mAbs with epitope specificities outlined in
Fig. 1. The SPR technique was used to quantitate the
antibody–peptide solution affinities, using Fab fragments
instead of whole mAb so that we could ensure that all
complexes had a 1 : 1 stoichiometry. The new multiply
substituted peptides turned out to be comparable with or
even better than the native antigen A15 in reactivity against
the mAbs. In addition, some positive nonadditivity towards
two of the three mAbs under study was observed for peptides
containing the Gly142 R Ser replacement. Both nuclear
magnetic resonance (NMR) and X-ray diffraction (Ochoa
et al., manuscript in preparation) data on one of the multiply
substituted peptides suggest that the structural features of
the multiple mutant are similar to those of the wild-type
sequence. These results, together with our previous studies
on other multiply substituted FMDV peptides (16–18)
provide strong evidence for antigen–antibody flexibility
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underlying degeneracy in antigenic recognition. For GH loop
peptides, in particular, recognition seems to rely on strict
conservation of those atoms directly interacting with
paratope groups, while allowing for a certain sequence
diversity in the rest of the sequence, as long as the bioactive
folding is preserved.
Results
Peptides
Thirty-three 15-residue peptides (Table 1) were synthesized,
one representing site A of FMDV C-S8c1 (A15), another as
Table 1. General data on the synthetic peptides under study
Peptide Sequence
Yield
(%)a
Purity
(%)b
MW
(MH+, Da)c
AAA
compositiond
A15Scr, negative control RAGTATTLADLHYST 87 94 1577.7 (1578) Asp, 1.03; Ser, 0.96; Gly, 1.01; Ala, 3.07; Leu, 1.98; His, 0.93
A15, GH loop of FMDV,
isolate C-S8c1
YTASARGDLAHLTTT 93 98 1577.6 (1578) Asp, 1.12; Ser, 0.98; Gly, 1.06; Ala, 3.00; Leu, 1.95; Tyr, 0.96
A15(137I) -I------------- 89 99 1589.2 (1589) Asp, 1.07; Ser, 1.04; Gly, 1.08; Ala, 3.10; Leu, 1.96; His, 0.92
A15(138F) --F------------ 65 97 1653.3 (1653) Asp, 0.96; Ser, 0.96; Gly, 1.03; Ala, 2.05; Leu, 2.05; His, 0.99
A15(140P) ----P---------- 84 98 1603.1 (1603) Asp, 1.04; Ser, 0.97; Gly, 1.05; Ala, 2.07; Leu, 1.96; Arg, 1.01
A15(142S) ------S-------- 79 99 1607.2 (1607) Asp, 1.05; Ser, 1.99; Ala, 3.08; Leu, 2.00; His, 0.92; Arg, 0.95
A15(148I) ------------I-- 87 98 1589.1 (1589) Asp, 1.05; Ser, 1.01; Gly, 1.04; Ala, 3.03; Leu, 1.86; Arg, 0.94
A15(137I,138F) -IF------------ 15 93 1665.1 (1665) Asp, 1.00; Ser, 0.98; Gly, 1.03; Ala, 1.98; Leu, 1.98; His, 1.02
A15(137I,140P) -I--P---------- 55 91 1615.6 (1615) Asp, 1.06; Ser, 1.00; Gly, 1.10; Ala, 1.93; Pro, 0.99; Arg, 1.02
A15(137I,142S) -I----S-------- 79 90 1619.2 (1619) Asp, 0.99; Ser, 2.07; Ala, 3.08; Leu, 2.03; His, 0.88; Arg, 0.95
A15(137I,148I) -I----------I-- 78 97 1601.3 (1601) Asp, 1.00; Ser, 0.99; Gly, 1.01; Ala, 3.04; His, 0.92; Arg, 0.99
A15(138F,140P) --F-P---------- 72 95 1679.6 (1679) Asp, 1.06; Pro, 1.01; Gly, 1.09; Ala, 1.05; Leu, 1.89; Arg, 1.07
A15(138F,142S) --F---S-------- 86 89 1684.1 (1684) Asp, 1.05; Ser, 2.10; Ala, 2.05; Leu, 1.88; His, 0.92; Arg, 1.00
A15(138F,148I) --F---------I-- 86 91 1665.4 (1665) Asp, 1.03; Ser, 0.95; Gly, 1.03; Ala, 2.00; His, 0.90; Arg, 1.09
A15(140P,142S) ----P-S-------- 81 87 1632.4 (1633) Asp, 1.02; Pro, 1.03; Ala, 2.04; Leu, 1.93; His, 0.92; Arg, 1.11
A15(140P,148I) ----P-------I-- 79 89 1615.6 (1615) Asp, 1.03; Ser, 0.95; Gly, 1.00; Ala, 2.01; His, 0.95; Arg, 1.07
A15(142S,148I) ------S-----I-- 79 86 1619.6 (1619) Asp, 1.05; Ser, 1.96; Ala, 3.10; Tyr, 0.87; His, 0.92; Arg, 1.14
A15(137I,138F,140P) -IF-P---------- 78 94 1691.6 (1691) Asp, 1.03; Ser, 0.96; Gly, 1.05; Ala, 1.01; Pro, 0.98; Arg, 1.05
A15(137I,138F,142S) -IF---S-------- 95 86 1694.5 (1695) Asp, 1.10; Ser, 1.90; Tyr, 0.91; Phe, 1.01; His, 0.97; Arg, 1.08
A15(137I,138F,148I) -IF---------I-- 83 95 1677.4 (1677) Asp, 1.01; Ser, 0.91; Gly, 1.01; Ala, 1.97; His, 1.07; Arg, 1.04
A15(137I,140P,142S) -I--P--S------- 82 94 1644.3 (1645) Asp, 1.03; Pro, 1.04; Ala, 2.01; Leu, 1.90; His, 0.91; Arg, 1.12
A15(137I,140P,148I) -I--P-------I-- 71 92 1626.6 (1627) Asp, 1.05; Ser, 0.99; Gly, 1.08; Ala, 1.93; Pro, 1.00; Arg, 1.03
A15(137I,142S,148I) -I----S-----I-- 80 92 1631.1 (1631) Asp, 1.05; Ser, 2.07; Ala, 2.97; Leu, 1.84; His, 0.96; Arg, 0.95
A15(138F,140P,142S) --F-P-S-------- 73 97 1708.3 (1709) Asp, 0.97; Ser, 1.97; Ala, 1.04; Leu, 2.08; Phe, 1.03; Arg, 1.02
A15(138F,140P,148I) --F- -P- ------I- 87 90 1690.1 (1691) Asp, 1.02; Pro, 1.00; Gly, 1.06; Ala, 1.02; Phe, 0.86; His, 0.90
A15(138F,142S,148I) --F---S-----I-- 88 91 1695.0 (1695) Asp, 1.07; Tyr, 0.87; Phe, 0.91; Ala, 2.09; Leu, 1.85; His, 1.07
A15(140P,142S,148I) ----P-S-----I-- 89 92 1645.0 (1645) Asp, 1.00; Pro, 1.02; Tyr, 0.93; Ala, 2.02; Arg, 1.11; His, 0.91
A15(137I,138F,140P,142S) -IF-P-S-------- 77 95 1720.9 (1721) Asp, 0.98; Ser, 1.91; Pro, 0.98; Ala, 0.99; Arg, 1.07; His, 1.07
A15(137I,138F,140P,148I) -IF-P-------I-- 74 94 1703.1 (1703) Asp, 0.99; Ser, 0.94; Gly, 1.03; Ala, 0.96; Pro, 0.96; Arg, 1.01
A15(137I,138F,142S,148I) -IF---S-----I-- 84 98 1706.7 (1707) Asp, 1.07; Ser, 2.06; Arg, 0.89; Ala, 2.04; Leu, 1.91; His, 0.93
A15(137I,140P,142S,148I) -I--P-S-----I-- 80 91 1656.0 (1657) Asp, 1.02; Ser, 1.91; Pro, 1.02; Ala, 1.98; Arg, 1.11; His, 0.96
A15(138F,140P,142S,148I) --F-P-S-----I-- 56 92 1721.2 (1721) Asp, 1.04; Ser, 2.01; Pro, 1.04; Ala, 1.01; Phe, 0.91; Arg, 1.08
A15(137I,138F,140P,142S,148I) -IF-P-S-----I-- 80 94 1732.1 (1733) Asp, 1.09; Ser, 2.03; Pro, 1.02; Ala, 1.05; Leu, 1.99; Arg, 0.95
a. Global yield: synthesis plus purification.
b. As percentage of peak area in HPLC.
c. Determined by either MALDI-TOF or ESI methods; theoretical mass in parenthesis.
d. Results for the six best matching residues in each hydrolysate. Contiguous Thr and Ile are known to hydrolyse nonquantitatively under standard
conditions.
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a negative control with scrambled sequence (A15Scr), and
31 other sequences corresponding to all possible (one-, two-,
three-, four- and five-point) combinations of the mutations
under analysis. All peptides were synthesized using Fmoc
solid-phase methods (27) with high yields (<80%), purified
(.90% by HPLC) and satisfactorily identified (AAA, ESMS,
MALDI-TOF MS) as the target sequences.
Solution affinity SPR analysis
The viability of direct kinetic biosensor analysis of the
interactions between immobilized anti-FMDV mAbs and
soluble 15-residue peptides has been previously demon-
strated (14,15,17,18,28). In this study, however, most
interactions could not be described kinetically, because of
high association rates, extremely slow dissociation rates or
incomplete surface regeneration (not shown). Deviations
from the ideal behavior (29) could be detected, thus
affecting true binding kinetics. Alternative indirect SPR
approaches (i.e. surface competition with a high molecular
mass analyte) (30) did not provide reliable means to study
the kinetics of the peptide–antibody interactions because of
inadequacy of the high molecular mass antigens assayed
(Gomes et al., unpublished data).
The inability to obtain kinetic data on the peptide–mAb
systems under study led us to the alternative solution
affinity approach. In the particular case of antigen–antibody
interactions, it must be ensured that reactions take place at
a 1 : 1 stoichiometry. Thus, instead of whole immuno-
globulins, Fab fragments produced by standard papain
digestion were employed. Injection of known Fab (SD6,
4C4 and 3E5) standards on the A15 surface allowed the
building of initial binding rate vs. Fab concentration
calibration curves (17,18), which were subsequently used
in the quantitation of Fab molecules that remained free
after overnight incubation with peptide antigens in solution.
Determination of the remaining free Fab in solution for
each incubated mixture (where Fab total concentration was
constant and peptide antigen concentrations varied) allowed
us to build inhibition curves (Fig. 2) from which the
peptide–antibody solution affinities were calculated using
the Cheng & Prusoff’s formula (eqn 1) (31). Results are
summarized in Table 2 and confirm the high peptide–
antibody affinities expected in view of the avidity effects
observed in the kinetic SPR analyses. These high peptide
antigenicities were in agreement with a competition ELISA
screening of these peptides using the same anti-GH loop
mAbs (Gomes et al., unpublished data) and with the avidity
effects observed in the initial kinetic approach.
The multiply substituted peptides displayed anti-
genicities that generally correlated with additive effects
in the combination of the different amino acid replace-
ments (Fig. 3), with an interesting systematic exception:
peptides including the Gly142 R Ser replacement vs. mAbs
4C4 and 3E5.
Affinity data
SPR screening of the substituted peptides showed the
one-point mutants to be closely equivalent in terms of
antigenicity (Table 2). Nonetheless, Ala138 R Phe and
Gly142 R Ser replacements negatively affected recognition
by mAb SD6; the second replacement, which involves the
RGD motif, was also disfavored by the other two mAbs.
The involvement of Ala138 in peptide–SD6 complexes (22)
and the important role of the RGD triplet are both in
agreement with previous observations (21,22,32,33). How-
ever, all mAbs were fully reactive with Thr137 R Ile and
Figure 1. Specificity of the anti-GH loop mAbs assayed. The minimal location of SD6, 4C4 and 3E5 epitopes, as deduced by studies with
synthetic peptides and variant viruses, is shown by a thick line; a thinner line indicates some effect on binding of the corresponding residues.
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Thr148 R Ile replacements, which is consistent with the
minimal participation of these residues in mAb–peptide
interaction, as seen by X-ray diffraction studies (16,21;
Ochoa et al., manuscript in preparation).
The multiply substituted peptides displayed, in general,
similar antigenicities (Table 2), in agreement to what was
expected from additive effects in the combination of the
one-point mutations (Fig. 3). However, for mAbs 4C4
and 3E5, affinities of multiple mutants containing the
Gly142 R Ser replacement were systematically higher
than expected from the ‘additivity rule’. Such deviations
suggest a small positive synergistic effect in these multiple
mutants.
Two-dimensional 1H NMR study of peptide A15(138F,140P,142S)
The absolute conformational chemical shifts for peptide
A15(138F,140P,142S) (Fig. 4) are comparable with those
previously observed for the native peptide A15 (34,35).
The global shape of the plots resembles those observed for
other GH loop peptides under identical conditions (34,35).
The region containing the open turn centered at the Arg-
Ser-Asp triplet is followed by an incipient helix, as usually
observed for other FMDV peptides (34,35). Moreover, the
almost identical plots obtained in either water or 30% TFE
(Fig. 4) suggest that the multiply substituted peptide is not
particularly sensitive to structure-inducing solvents, and
thus is conformationally stable. These findings are further
supported by the observation of a few (weak but informative)
NNi,i+1 and NNi,i+2-type NOEs (not shown), consistent
with the nascent helical path in the Ser142–His146 region
mentioned above.
Discussion
Anti-GH loop mAbs have previously been reported to
display higher than expected reactivities towards multiply
substituted FMDV peptides (10,13). This positive non-
additivity has been attributed to peptide folding properties,
where less favorable conformational effects caused by a
given amino acid replacement could be compensated by
introduction of additional residue substitutions, leading to
the recovery of the bioactive folding pattern (Fig. 5A) (16).
Our results similarly suggest that the decrease in affinity
provoked by the Gly142 R Ser replacement in the 141–143
open turn is adequately counterbalanced by substitutions
outside this region. Indeed, when the triply substituted
A15(138F,140P,142S) peptide was studied in solution using
2D 1H NMR, conformational features similar to those
characterizing the native A15 could be detected. Further,
the antigenically relevant open-turn motif centered at the
RSD triplet was conformationally stable and involved a
higher number of residues than in the wild-type peptide,
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Figure 2. Variation of remaining free Fab at equilibrium (total [Fab]580 nm) with competitor peptide concentration (from 0 to 600 nm). For
clarity, only inhibition curves for Fab 4C4 vs. peptides A15, A15Scr, A15(138F), A15(140P), A15(142S) and A15(138F,140P,142S) are displayed.
Gomes et al . Degeneracy in antibody–antigen recognition
J. Peptide Res. 59, 2002 / 221–231 | 225
ranging from the non-native Pro140 to Leu147. This turn-
stabilizing effect of the Ala140 R Pro replacement has also
been observed in a parallel X-ray diffraction study of the
complex between Fab 4C4 and this mutant peptide (Ochoa
et al., manuscript in preparation). This diffraction study
furnished valuable additional information regarding the
other two replacements: (i) the aromatic ring of Phe138
points outwards of the peptide pseudo-cycle (Fig. 5A),
engaging in hydrophobic interactions with the mAb bind-
ing pocket and not disrupting intrapeptide interactions;
(ii) the side-chain hydroxyl of Ser142 effectively replaces
the water molecule present in complexes of mAbs with
(native) 142Gly-containing peptides. Either the water
molecule or the Ser hydroxyl contribute to an intrapeptide
hydrogen bond network connecting main chain heteroatoms
of residues 139 and 144 (Figs 5B,C).
In conclusion, our study of this family of peptides from
the FMDV immunodominant site reinforces previous
evidence (17,18,28) that antigenicity is compatible with
substantial sequence variability in peptides based on the GH
loop, provided two key requisites are fulfilled: (i) residues
involved in direct epitope–paratope contacts (Arg141, Asp143,
Leu144, His146) must be conserved; (ii) conformationally
important residues may be replaced by others equally
able to engage in intrapeptide interactions promoting the
bioactive conformation, i.e. a quasicyclic folding sup-
ported by interactions between N-terminal Ala138, Ser139
and C-terminal Leu144,147 residues, respectively. Amino
acid replacements that not only do not disrupt, but also help
to promote these essential requirements can yield variant
peptides with significant reactivity towards anti-FMDV
neutralizing mAbs, altogether providing a significant
example of degeneracy in antigen-antibody recognition
mechanisms.
Materials and methods
Peptide synthesis and purification
Peptides (Table 1) were prepared as C-terminal carboxa-
mides using solid-phase methods in an AMS 422
multiple peptide synthesizer (Abimed, Germany) using
Fmoc/tBu chemistry on an AM-MBHA resin (Novabiochem,
0.51 mmol/g). The synthesis was performed at a
0.025-mmol scale, using 20% piperidine (Aldrich) in DMF
(Scharlau) for Fmoc deprotection. Couplings were carried
out with 4 eq. of Fmoc-amino acid (Bachem), 4 eq. of TBTU
(Neosystem) and 8 eq. of NMM (Merck) for 1 h. Peptides
were cleaved from the resin and deprotected by treatment
with 1 mL of TFA (Kalichemie)/Et3SiH (Aldrich)/H2O
(95 : 2.5 : 2.5 v/v/v) for 2 h. The crude peptides were
precipitated from the TFA solution by treatment with cold
Table 2. Association binding constants from
solution affinity SPR
Peptidea
Ki
c,d/M–1
mAb SD6
Ki
c,d/M–1
mAb 4C4
Ki
c,d/M–1
mAb 3E5
A15Scrb – – –
A15 6.33107 2.03108 2.03108
A15(137I) 8.53107 2.03108 1.43108
A15(138F) 3.63107 2.13108 2.13108
A15(140P) 7.13107 1.83108 1.63108
A15(142S) 2.73107 7.33107 6.23107
A15(148I) 6.73107 2.03108 2.03108
A15(IF) 5.13107 2.23108 1.63108
A15(IP) 6.13107 2.13108 1.33108
A15(IS) 5.23107 1.93108 1.33108
A15(II) 9.13107 2.33108 2.03108
A15(FP) 2.83107 2.23108 2.03108
A15(FS) 7.13106 2.03108 1.63108
A15(FI) 2.13107 2.13108 1.93108
A15(PS) 3.63107 2.03108 6.23107
A15(PI) 6.03107 1.83108 1.93108
A15(SI) 1.63107 1.93108 1.23108
A15(IFP) 7.43107 2.23108 1.93108
A15(IFS) 2.03107 8.53107 5.93107
A15(IFI) 5.63107 2.43108 1.83108
A15(IPS) 7.43107 2.23108 1.43108
A15(IPI) 7.93107 2.23108 2.03108
A15(ISI) 4.53107 2.23108 1.73108
A15(FPS) 6.53106 2.13108 1.33108
A15(FPI) 5.03107 1.33108 1.83108
A15(FSI) 1.33107 2.13108 1.53108
A15(PSI) 2.53107 2.13108 1.53108
A15(IFPS) 4.73107 2.23108 1.33108
A15(IFPI) 7.13107 2.03108 1.83108
A15(IFSI) 1.93107 2.13108 1.23108
A15(IPSI) 5.03107 1.53108 1.33108
A15(FPSI) 1.73107 2.23108 1.33108
A15(IFPSI) 3.83107 1.93108 1.73108
a. Peptide abbreviated names are presented, with only
the single-letter codes of the mutated residues being
shown; full peptide sequences are displayed in Table 1;
b. As depicted in Fig. 2, binding of negative control
peptide (A15Scr) to mAbs could not be detected;
c. Ki (association binding constants) calculated from
experimental data (inhibition curves as depicted in
Fig. 5) by application of the Cheng & Prusoff’s formula
(see text);
d. Ki values .20% higher than Ki(A15) are shown in
bold; Ki values .10% lower than Ki (A15) are shown in
italics.
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Figure 3. Comparison between measured and calculated affinities (Ki) assuming additive effects on the combinations of the different amino acid
replacements: Fab fragments of mAbs (A) SD6, (B) 4C4 and (C) 3E5. (a) Calculated Ki (multiple-mutant peptide, e.g. with mutations 1, 2 and
4)5Krel (single-mutant 1)3Krel (single-mutant 2)3Krel (single-mutant 4)3Ki (peptide A15), where Krel5measured Ki (single-mutant x)/measured Ki
(reference peptide A15). (b) Peptide nomenclature has been changed for conciseness: each peptide is named after the single letter codes of the
residues replacing native ones. Thus, FSI stands for A15(138F,142S,148I). (c) Peptides giving affinities higher than expected from additivity
calculations are marked with an asterisk.
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Figure 4. Conformational chemical shift plots (DdHa) from the 2D 1H NMR analysis of peptide A15(138F,140P,142S) in water and in 30% TFE.
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tert-butyl methyl ether (Fluka), redissolved in 10% acetic
acid (Merck), lyophilized and purified by reverse-phase
liquid chromatography, using a linear 5 R 25% gradient of
MeCN (Scharlau) in water with 0.05% TFA on a Vydac C18
reverse phase column (250325 mm, 15–20 mm, 300 A˚).
Purified peptides were satisfactorily characterized by AAA
(Beckman 6300), HPLC (Waters or Shimadzu instruments;
Nucleosil C18 columns, 25034 mm, 5 mm, 120 A˚) and
ESMS (Fisons VG Quattro) or MALDI-TOF MS (Brucker II
Biflex).
Solutions for SPR analysis
Peptide stock solutions,< 2.5 mm in 0.1 m acetic acid, were
prepared and quantitated by AAA. Solutions for BIAcore
analysis were obtained by 1000-fold and subsequent serial
dilutions in HBS. Stock solutions of mAbs SD6 and 4C4
(supplied by Dr Esteban Domingo, Center for Molecular
Biology, Madrid, Spain), in PBS with 0.02% sodium azide,
pH 7.3, were quantitated using the Pierce BCA assay. mAb
3E5 was purified from ascitic fluid (supplied by Dr Emiliana
Brocchi; Istituto Zooprofilattico, Brescia, Italy) using a
HiTrap Protein A affinity column (Pharmacia Biotech) and
quantitated spectrophotometrically (1 OD28050.75 mg/mL).
For solution affinity SPR assays, PBS solutions (<16 mg/
mL) of the Fab fragments. The Fab fragments were kindly
provided by Dr Esteban Domingo, except for Fab 3E5, which
was prepared by papain digestion as follows. mAb 3E5 was
purified from ascitic fluid as described above and con-
centrated by precipitation with 45% ammonium sulfate; the
suspension was centrifuged (10 000 r.p.m., 48C) for 20 min
and pellet was resuspended in the minimum volume of PBS
and dialyzed overnight against PBS (331 L). Antibody (3 mg
in 2 mL of PBS) and papain (30 mg in 24 mL 0.1 m EDTA,
126 mL 100 mm cysteine) solutions were mixed, diluted
to 3 mL and incubated at 378C for 5 h; the reaction was
quenched with iodoacetamide (80 mL) and the digest was
analyzed by SDS–PAGE on a 12% acrylamide gel, using
mAb and Fab 4C4 as standards. Proteins in the digest
were precipitated with 85% ammonium sulfate and
centrifuged (48C, 10 000 r.p.m.) for 20 min; pellet was
resuspended in minimal volume of 1 : 1 PBS/buffer A
(112.4 g/L glycine, 175.4 g/L NaCl, pH 8.9 adjusted with
NaOH), dialyzed overnight against buffer A (331 L);
centrifuged at 12 000 r.p.m. (48C) to remove remaining
solid particles, and eluted through a protein A–Sepharose
column. Fractions with OD280$0.5 (first elution peak)
were pooled and concentrated to a final volume of 2 mL
using a Centriprep-3 concentrator (Amicon) at 2000 r.p.m.;
Fab 3E5 was filtered through Sephadex G-100 in PBS (20 mL/
h; 48C); protein-containing fractions (monitored at 280 nm)
were pooled, concentrated (Centriprep-3) and quantitated by
optical density at 280 nm.
Figure 5. (A) Superimposed structures of multiply substituted peptides in complex with Fab 4C4. (B) Detail of the native RGD loop (note the
water molecule bridging residues 139 and 144). (C) Detail of the mutated RSD loop (note the side chain OH group of Ser142 bridging residues 139
and 144). These graphic representations of structures from crystallographic data were processed using the setor program (42).
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Solution affinity SPR analysis
A sensor chip surface containing the wild-type peptide A15
was prepared according to the manufacturer’s instructions: a
5-mL/min HBS continuous flow was maintained and the
carboxymethyl surface was activated by a 7-min injection of
a solution containing 0.2 m EDC and 0.05 m NHS. A15
surfaces were obtained by injecting 35 mL of a 200 mg/mL
A15 solution in 10 mm sodium acetate buffer, pH 5.5.
Unreacted activated groups were blocked by a 6-min
injection of ethanolamine and remaining noncovalently
bound molecules were washed off with a 3-min pulse of
50 mm HCl. The final immobilization response was
<260 RU, corresponding to a high surface peptide density
(0.26 ng/mm2) that favors mass-transport limitations (36).
Different solutions of Fab in HBS with known concentra-
tions were injected over the A15 sensor chip surface at
5 mL/min and initial binding rates (proportional to analyte
concentration under diffusion-controlled kinetics) were
measured from the slopes of the sensorgrams at earlier
stages of the injection (at about the 100th second, to avoid
influence from initial bulk refractive index ‘jumps’). The
calibration curve initial binding rate vs. Fab concentration
was built and fitted to a 4-parameter equation using the
biaevaluation 3.0.2 software. This equation was then
used to calculate free Fab concentrations on subsequent
assays.
Peptide–Fab interactions were studied by overnight
incubation at 48C of varying peptide concentrations with a
constant 80 nm total Fab concentration in HBS, followed by
SPR quantitation of the remaining free Fab at equilibrium.
Fab–peptide mixtures were allowed to re-equilibrate at 258C,
prior to injection on the A15 surface for Fab quantitation.
Free Fab dependence on peptide concentration was plotted
and the affinity binding constant Ki was calculated using the
Cheng & Prusoff’s formula (31):
Ki ¼ 1 þ KA½Fab
IC50
ð1Þ
where IC50 is the concentration of peptide competitor giving
a 50% decrease in Fab concentration and KA is the
immobilized peptide A15–antibody affinity previously
measured by direct kinetic SPR analysis (14,15,17,18).
Two-dimensional 1H RMN of peptide A15(138F,140P,142S)
Spectra were acquired at 258C, both in aqueous solution
(85% H2O+15% D2O) and in the presence of the structure-
promoting agent TFE (30% TFE+60% H2O+10% D2O) at a
peptide concentration of 2 mm, with 1,4-dioxane added as an
internal reference. All experiments were carried out on a
Varian VXR-500S NMR spectrometer and further processed
with the vnmr software programs. The 2D 1H NMR (37)
experiments performed were (i) TOCSY (38) (70 ms mixing
time), (ii) NOESY (39) (200 or 400 ms mixing time), and (iii)
ROESY (40) (200 ms mixing time). Water signal elimination
was carried out either upon presaturation or using the
WATERGATE (41) method. Prior to the Fourier transform,
both FIDs and interferograms were multiplied by an
exponential function.
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